Durvalumab
AstraZeneca
[]
looking forward to presenting this data at the #aacr23 major symposium tomorrow, leading to our discovery of persistent mutations, a biologically distinct subset within the overall tmb that cannot be eliminated by chromosomal deletions. stop by valencia a at 12.30p! 
Director, @MolecularOncLab & @HopkinsThoracic Biorepository
Co-leader, Molecular Tumor Board @hopkinskimmel. 
Bringing multi-omics discoveries into IO trials.